Global Prostate Health Market

Report ID : 1402 | Published : 2022-10-13 | Pages: | Format: PDF/EXCEL

The market size of the global Prostate Health market in the year 2021 is valued at 29.81 billion and is predicted to reach 62.40 billion by the year 2030 at an 8.83% CAGR during the forecast period.

Prostate cancer is a type of cancer that can develop in men. The little gland produces seminal fluid. It is the second most significant cause of death for men in the US. Some prostate cancers have a sluggish growth rate, are only found in the prostate gland, and may not show any harm. Others may spread swiftly and cause serious injury, while some may need therapy. Rising obesity, lifestyle disorders, smoking, and the development of cutting-edge prostate cancer diagnosis and treatment techniques contribute to the market's revenue growth. Additionally, growing investments by major corporations and governments of several nations throughout the world in the development of novel medicines and equipment to prevent and treat prostate cancer are also propelling market revenue growth due to the FDA's support of emerging technologies and medications in the pipeline, as well as the market for prostate health, which is anticipated to rise significantly. Over the predicted time range, it is anticipated that government FDA approvals will create numerous growth opportunities for the prostate cancer health industry.

The creation of breakthrough treatments like PSMA-targeted therapy and technological advancements accelerate the market's revenue growth. In addition, it is projected that the market will generate more money as demand for prostate cancer and hormone therapy treatments rises. However, the side effects of BPH and prostate health treatments and drugs prevent market expansion in the short term. Prostate cancer and its therapies, such as surgery, radiation, and hormone therapy, can potentially cause erectile dysfunction. It is projected that these factors will restrain market revenue growth.

Market Segmentation:

The Prostate Health market is segmented on disease indication, treatment and distribution channels. Based on disease indication, the market is segmented into Prostate Cancer, Prostatitis, Alpha Blockers, Benign Prostate Hyperplasia and Others. Based on the treatment,  Prostate Health is segmented into Cytotoxic Agents, Hormone ADT, AR Directed Therapies, PARP Inhibitors and Others. Based on end-user, the market is segmented into Hospitals, Specialty Clinics, Homecare and Others. Based on distribution channel, the market is segmented into Pharmacies, E-commerce Stores and Others.

Based on treatment, the Hormone ADT segment is accounted as a major contributor to the Prostate Health market.

Based on the treatment,  Prostate Health is segmented into Cytotoxic Agents, Hormone ADT, AR Directed Therapies, PARP Inhibitors and Others. The hormone ADT category held the largest revenue share. Prostate cancer is fueled by the male sex hormone androgens, which can also slow the disease's spread. It is widely accepted that ADT is the first line of treatment for symptomatic metastatic prostate cancer. The most common androgen is testosterone. Androgen Deprivation Therapy (ADT) hormone therapy is used to lower testosterone levels in the body by surgically removing testicles or taking drugs that make testicles inactive. Hormone treatment can be used to treat prostate cancer in various situations, including localized, locally advanced, and metastatic illness, as well as rising PSA levels after localized prostate cancer surgery and radiation therapy, which is anticipated to propel this market's revenue growth.

The e-commerce stores segment witnessed growth at a rapid rate.

Based on distribution channel, the market is segmented into Pharmacies, E-commerce Stores and Others. The e-commerce stores category dominates the market. Online pharmacies are convenient, grow swiftly, and are replacing traditional drugstores. It's easy and convenient for folks who live far from actual pharmacies and older adults to buy prescription drugs online. Additionally, e-commerce stores save money and time. Simply ordering prescription medications online is possible. It is not necessary to go to a pharmacy and wait in line.

The North America Prostate Health market holds a significant revenue share in the region.

The North America Prostate Health market is expected to register the highest market share in revenue in the near future due to the rising frequency of BPH and advancements in therapy. Additionally, favourable reimbursement policies, research funding, a robust healthcare infrastructure, and an increase in product introductions have all contributed to the expansion of the prostate health industry in the area. In addition, Asia Pacific is projected to grow rapidly in the global Prostate Health market. Throughout the projection period, emerging nations in the Asia Pacific, such as China, India, Brazil, and Mexico, are anticipated to increase and present potential prospects for various market players. The need for prostate health solutions in the Asia Pacific is also anticipated to rise as a result of increasing healthcare investments, a rise in physician awareness, and an ageing population.

Competitive Landscape

The key players in the Prostate Health market have shifted their focus toward product manufacturing and are initiating significant strategies such as mergers, acquisitions, and joint ventures of major and domestic players to enhance product portfolio and strengthen their global market footprint. Some major key players in the Prostate Health market are Pfizer Inc., Lily, Bayer AG, Abbolt, GSK plc., Merck KGaA, ProArc, Nucleai, Inc., Sanofi, and AbbVie Inc.

Chapter 1. Methodology and Scope

1.1. Research Methodology

1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Prostate Health Market Snapshot

Chapter 4. Global Prostate Health Market Variables, Trends & Scope

4.1. Market Segmentation & Scope

4.2. Drivers

4.3. Challenges

4.4. Trends

4.5. Investment and Funding Analysis

4.6. Industry Analysis – Porter’s Five Forces Analysis

4.7. Competitive Landscape & Market Share Analysis

4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Disease Indication Estimates & Trend Analysis

5.1. by Disease Indication & Market Share, 2019 & 2030

5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Disease Indication:

5.2.1. Prostate Cancer

5.2.2. Prostatitis

5.2.3. Alpha Blockers

5.2.4. Benign Prostate Hyperplasia

5.2.5. Others

Chapter 6. Market Segmentation 2: by Treatment Estimates & Trend Analysis

6.1. by Treatment & Market Share, 2019 & 2030

6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Treatment:

6.2.1. Hormone ADT

6.2.2. AR Directed Therapies

6.2.3. PARP Inhibitors

6.2.4. Others

Chapter 7. Market Segmentation 3: by Distribution Channel Estimates & Trend Analysis

7.1. by Distribution Channel & Market Share, 2019 & 2030

7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2019 to 2030 for the following by Distribution Channel:

7.2.1. Pharmacy

7.2.2. E-commerce Stores

7.2.3. Others

Chapter 8. Prostate Health Market Segmentation 4: Regional Estimates & Trend Analysis

8.1. North America

8.1.1. North America Prostate Health Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2022-2030

8.1.2. North America Prostate Health Market Revenue (US$ Million) Estimates and Forecasts by Treatment, 2022-2030

8.1.3. North America Prostate Health Market revenue (US$ Million) by Distribution Channel, 2022-2030

8.1.4. North America Prostate Health Market Revenue (US$ Million) Estimates and Forecasts by country, 2022-2030

8.2. Europe

8.2.1. Europe Prostate Health Market revenue (US$ Million) by Disease Indication, 2022-2030

8.2.2. Europe Prostate Health Market revenue (US$ Million) by Treatment, 2022-2030

8.2.3. Europe Prostate Health Market revenue (US$ Million) by Distribution Channel, 2022-2030

8.2.4. Europe Prostate Health Market revenue (US$ Million) by country, 2022-2030

8.3. Asia Pacific

8.3.1. Asia Pacific Prostate Health Market revenue (US$ Million) by Disease Indication, 2022-2030

8.3.2. Asia Pacific Prostate Health Market revenue (US$ Million) by Treatment, 2022-2030

8.3.3. Asia-Pacific Prostate Health Market revenue (US$ Million) by Distribution Channel, 2022-2030

8.3.4. Asia Pacific Prostate Health Market revenue (US$ Million) by country, 2022-2030

8.4. Latin America

8.4.1. Latin America Prostate Health Market revenue (US$ Million) by Disease Indication, 2022-2030

8.4.2. Latin America Prostate Health Market revenue (US$ Million) by Treatment, 2022-2030

8.4.3. Latin America Prostate Health Market revenue (US$ Million) by Distribution Channel, 2022-2030

8.4.4. Latin America Prostate Health Market revenue (US$ Million) by country, 2022-2030

8.5. Middle East & Africa

8.5.1. Middle East & Africa Prostate Health Market revenue (US$ Million) by Disease Indication, 2022-2030

8.5.2. Middle East & Africa Prostate Health Market revenue (US$ Million) by Treatment, 2022-2030

8.5.3. Middle East & Africa Prostate Health Market revenue (US$ Million) by Distribution Channel, 2022-2030

8.5.4. Middle East & Africa Prostate Health Market revenue (US$ Million) by country, 2022-2030

Chapter 9. Competitive Landscape

9.1. Major Mergers and Acquisitions/Strategic Alliances

9.2. Company Profiles

9.2.1. Pfizer Inc.

9.2.2. Lily

9.2.3. Bayer AG

9.2.4. Abbolt

9.2.5. GSK plc.

9.2.6. Merck KgaA

9.2.7. ProArc

9.2.8. Nucleai, Inc.

9.2.9. Sanofi

9.2.10. AbbVie Inc

9.2.11. Other Prominent Players

By Disease Indication-

  • Prostate Cancer
  • Prostatitis
  • Alpha Blockers
  • Benign Prostate Hyperplasia
  • Others

By Treatment-

  • Cytotoxic Agents
  • Hormone ADT
  • AR Directed Therapies
  • PARP Inhibitors
  • Others

By Distribution Channel

  • Pharmacy
  • E-commerce Stores
  • Others

By Region-

North America-

  • The US
  • Canada
  • Mexico

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • South East Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of Middle East and Africa

InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.

Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.

Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.

Secondary research

The secondary research sources that are typically mentioned to include, but are not limited to:

  • Company websites, financial reports, annual reports, investor presentations, broker reports, and SEC filings.
  • External and internal proprietary databases, regulatory databases, and relevant patent analysis
  • Statistical databases, National government documents, and market reports
  • Press releases, news articles, and webcasts specific to the companies operating in the market

The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista

Primary Research:

Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies

The contributors who typically take part in such a course include, but are not limited to: 

  • Industry participants: CEOs, CBO, CMO, VPs, marketing/ type managers, corporate strategy managers, and national sales managers, technical personnel, purchasing managers, resellers, and distributors.
  • Outside experts: Valuation experts, Investment bankers, research analysts specializing in specific markets
  • Key opinion leaders (KOLs) specializing in unique areas corresponding to various industry verticals
  • End-users: Vary mainly depending upon the market

Data Modeling and Analysis:

In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.

The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.

To know more about the research methodology used for this study, kindly contact us/click here.

Need Complete Report ?
Our Clients